%0 Journal Article %A Lil Meyer-Arndt %A Tatjana Schwarz %A Lucie Loyal %A Larissa Henze %A Beate Kruse %A Manuela Dingeldey %A Kübrah Gürcan %A Zehra Uyar-Aydin %A Marcel A. Müller %A Christian Drosten %A Friedemann Paul %A Leif E. Sander %A Ilja Demuth %A Roland Lauster %A Claudia Giesecke-Thiel %A Julian Braun %A Victor M. Corman %A Andreas Thiel %T Serum but not mucosal antibody responses are associated with pre-existing SARS-CoV-2 spike cross-reactive CD4+ T cells following BNT162b2 vaccination in the elderly %D 2021 %R 10.1101/2021.10.05.21264545 %J medRxiv %P 2021.10.05.21264545 %X Advanced age is a main risk factor for severe COVID-19. However, low vaccination efficacy and accelerated waning immunity have been reported in this age group. To elucidate age-related differences in immunogenicity, we analysed human cellular, serological and salivary SARS-CoV-2 spike glycoprotein-specific immune responses to BNT162b2 COVID-19 vaccine in old (69-92 years) and middle-aged (24-57 years) vaccinees compared to natural infection (COVID-19 convalescents, 21-55 years). Serological humoral responses to vaccination exceeded those of convalescents but salivary anti-spike subunit 1 (S1) IgA and neutralizing capacity were less durable in vaccinees. In old vaccinees, we observed that pre-existing spike-specific CD4+ T cells are associated with efficient induction of anti-S1 IgG and neutralizing capacity in serum but not saliva. Our results suggest pre-existing SARS-CoV-2 cross-reactive CD4+ T cells as predictor of an efficient COVID-19 vaccine-induced humoral immune response in old individuals.Competing Interest StatementVMC and MAM are named together with Euroimmun on a patent application filed recently regarding detection of antibodies against SARS-CoV-2.Funding StatementGerman Federal Ministery of Health to AT (Charite Corona Cross (CCC)) and to CD and VMC (Konsiliarlabor fuer Coronaviren). German Ministry of Research through VARIPath (01KI2021) to VMC. German Research Foundation through KFO339 to JB. In part by the German Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung, BMBF) to NaFoUniMedCovid19, COVIM, FKZ 01KX2021.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee Charite - Universitaetsmedizin BerlinI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during the current study are available from the corresponding author on reasonable request.COVID-19coronavirus disease 2019d28day 28 after first vaccinationd49day 49 after first vaccination∼d28around day 28 after COVID-19 symptom onset∼d49around day 49 after COVID-19 symptom onset∼d94around day 94 after COVID-19 symptom onsetSARS-CoV-2severe acute respiratory syndrome coronavirus 2sIgAsecretory IgAsVNTsurrogate virus neutralization assayS1SARS-CoV-2 spike glycoprotein subunit 1S-Ipeptide mix representing the SARS-CoV-2 spike glycoprotein N-terminal partS-IIpeptide mix representing the SARS-CoV-2 spike glycoprotein C-terminal part mix %U https://www.medrxiv.org/content/medrxiv/early/2021/12/19/2021.10.05.21264545.full.pdf